Category: BioTech
The analysis published under this category are as follows.
Friday, September 13, 2013
Hidden Finds in Biotech Regenerative and Medical Technology / Companies / BioTech
By: TLSReport
Ladenburg Thalmann & Co. Inc.'s Jeff Cohen regularly explores the frontiers of regenerative and medical technology looking for solid investment opportunities. In this interview with The Life Sciences Report, Cohen reveals promising finds in one of the world's fastest-growing business sectors. From robotics to skin grafts, Cohen knows his science and his market.
The Life Sciences Report: Can you tell me a little bit about your role as an analyst at your firm?
Read full article... Read full article...
Thursday, September 05, 2013
Neurotechnology Investing - Digging Below the Surface / Companies / BioTech
By: TLSReport
Neuroscience is about as complex as it gets. The central nervous system contains the brain and spinal cord, where hundreds of billions of neurons are located—and that doesn't include the peripheral nervous system. Casey Lynch, managing director of NeuroInsights, works to make sense of both the disease processes affecting the nervous system and potential therapies that could help patients and enrich investors. In this interview with The Life Sciences Report, Lynch brings some clarity to the complexity, and speaks frankly about the wild goose that some Alzheimer's disease investigators have been chasing.
Friday, August 30, 2013
Biotech Stocks Investor Realism / Companies / BioTech
By: TLSReport
Expert healthcare company watcher Andrew Fein of H.C. Wainwright & Co. knows how the sausage is made in the stock analyst factory. And he doesn't pull any punches: In this interview with The Life Sciences Report, Fein dishes out praise for sticking to sellside fundamentals and suggests skimming off bloggers who have yet to earn their analytical chops. He rounds out the menu by naming biotech companies with the potential to rise to the top of the simmering biotech market.
The Life Sciences Report: How has the nature of biotech investing changed since you began analyzing healthcare biotech equities in 2000?
Read full article... Read full article...
Wednesday, August 28, 2013
Amgen Onyx Deal, The Fastest Route To Biotech Profit Now / Companies / BioTech
By: Money_Morning
Tara Clarke writes: On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal - making it the fifth-largest biotech deal in history according to Standard & Poor's Capital IQ.
Friday, August 16, 2013
Still Time to Catch Big Growth in Biotech Stocks / Companies / BioTech
By: TLSReport
Biotech has had a scorching run for more than a year and a half, but as broader markets approach more realistic valuations with less potential upside, it becomes even more important to be invested in the right companies with truly meaningful catalysts on the horizon. George Zavoico of MLV & Co. knows how to pick winners from the field, and offers up solid ideas with visible growth drivers in this interview with The Life Sciences Report. Your inner gambler should take note: A beaten-down micro- or small-cap company might, with a bit of luck, bring home the gold.
Monday, August 05, 2013
The Worry-Free Way of Investing in Biotech Stocks / Companies / BioTech
By: Money_Morning
Greg Madison writes: If there's one sector that's primed for explosive growth right now, it's biotechnology.
Its position as a new market leader in the tech sector cannot be overstated. Clearly, investing in biotech is an idea few can afford to ignore.
Read full article... Read full article...
Thursday, August 01, 2013
Seven Extraordinary Biotech and Medtech Companies / Companies / BioTech
By: TLSReport
Senior Biotechnology Analyst Jason Napodano of Zacks Investment Research specializes in uncovering small biotech and medtech companies with good prospects for successful drug development. He relishes proven management capable of creative financing to move private equity into the public markets, and he does not shy away from tiny companies outside the U.S. that have extraordinary technology. In this wide-ranging interview with The Life Sciences Report, Napodano presents the elegant growth stories of seven small companies that could return magnificent gains to investors.
The Life Sciences Report: Jason, you follow some companies that are not domiciled in the U.S. Are there special considerations or concerns that investors should be aware of before investing in stocks outside U.S. markets?
Read full article... Read full article...
Sunday, July 28, 2013
Is Cell Therapy the 'Future of Medicine'? / Companies / BioTech
By: TLSReport
The pricey evolutionary tradeoff for walking on two legs is the curse of lower back pain. Jason Kolbert of the Maxim Group understands the power of stem cells as disease-modifying therapies for degenerative disc disease of the spine, a leading-edge, multibillion-dollar indication. Kolbert explores the opportunities that cell therapies offer investors in this interview with The Life Sciences Report, and puts a personal spin on their regenerative promise.
The Life Sciences Report: Jason, I wanted to ask you some questions about degenerative disc disease (DDD) and the use of cell therapy to manage the problem. Some people have said that the spine is a hostile environment. Why is it hostile?
Read full article... Read full article...
Monday, July 22, 2013
The Best Biotech Stocks for 2013 are Now Within Your Reach / Companies / BioTech
By: Money_Morning
Garrett Baldwin writes: Biotech stocks are soaring in 2013 as major innovations in healthcare have offered enormous breakthroughs on once-untreatable diseases and conditions.
But for years, it was tricky to invest in some of today's best biotech companies given their volatility and uncertainty in the industry. For the better part of five years, some of today's leading biotech stocks remained essentially flat.
Read full article... Read full article...
Wednesday, July 10, 2013
How to Ride the Biotech Boom / Companies / BioTech
By: Investment_U
Marc Lichtenfeld writes: hope you had a great Fourth of July. I had a blast hanging out with family and friends. However, we had a long drive home so we missed the fireworks.
That’s OK, though. I’ve seen plenty of fireworks in the past two weeks in the biotech sector.
Since June 24, the Amex Biotech Index (NYSE: BTK) is up over 11%. That’s a solid year for most indexes. Year to date, the group is up over 34%.
Read full article... Read full article...
Sunday, June 23, 2013
Deadly Bacteria Is a Global Health Crisis and Investor Opportunity / Companies / BioTech
By: TLSReport
Antibiotic-resistant bacteria, like the proverbial time bomb, are poised to wreak infectious havoc on a worldwide scale. Brad Spellberg, associate professor of medicine at the Los Angeles Biomedical Research Institute and the Harbor-UCLA Medical Center, is committed to defusing the bomb with the development of new antibiotics and creative platforms. He believes investigators must look at alternative ways to deal with bad bugs, perhaps by neutralizing their toxic effects rather than killing them. In this interview with The Life Sciences Report, Spellberg explores this critical issue and names four companies with novel technologies that address this looming global crisis.
The Life Sciences Report: The first thing I want to ask is if you believe it's a hopeful sign that young physicians are less likely to prescribe antibiotics, especially at the patient's request? Isn't that a sign that residents and fellows are being trained with increasing awareness of bacterial resistance, an issue that is so important to you?
Read full article... Read full article...
Friday, June 21, 2013
How to Double Your Money by Investing in Biotech / Companies / BioTech
By: Money_Morning
Diane Alter writes: Some of the most lucrative opportunities you can find now are in the biotechnology industry – which is why we've been working to uncover the best ways for how to invest in this sector.
The best biotech companies overflow with innovation. They can offer a steady stream of game-changing products – which often translates to record-breaking revenue.
Read full article... Read full article...
Thursday, June 20, 2013
How to Profit from the Supreme Court DNA Patenting Ruling / Companies / BioTech
By: Money_Morning
Tara Clarke writes:
A rather complicated U.S. Supreme Court ruling in Association for Molecular Pathology v. Myriad Genetics, Inc. came out last week on whether life or more specifically DNA can be patented.
I don't want to talk about the science behind the ruling. It gets complicated. Rather, I'd like to simply breakdown how the High Court's decision can affect your wallet.
Read full article... Read full article...
Monday, June 17, 2013
Deadly Saudi MERS-CoV Global Pandemic Bio-tech Stocks Profit Potential / Companies / BioTech
By: Money_Morning
Greg Madison writes: One of the really beneficial things about science is its power to transcend borders and ideologies. Scientists in countries that may be totally hostile to one another have the chance of collaborating on difficult problems in a spirit of openness.
This ability to collaborate and exchange information across borders is particularly important when a new disease with global pandemic potential emerges, as it has in the Middle East with the respiratory system coronavirus (MERS-CoV).
Read full article... Read full article...
Tuesday, May 07, 2013
What Could Be the Most Lucrative Time Ever for Biotech Investing / Companies / BioTech
By: Money_Morning
Tim Melvin writes: Some of the most exciting developments in the last fifty years have been in the biotechnology industry - which has also meant the emergence of some of the best investments for 2013.
Just look at the progress biotech has made in medicine.
Read full article... Read full article...
Friday, May 03, 2013
Exciting Biotech Stocks Investing Ideas Have Explosive Potential / Companies / BioTech
By: TLSReport
In January 2013, The Life Sciences Report debuted its biotech Watchlist, which outlined ideas for investors keyed to catalysts in the drug development process that typically move biotechnology stocks. All stocks are affected by catalysts, but nowhere do they provide more leverage (or deleverage) than in biotech. We predicted the new year would present legitimate prospects for portfolio growth. So far, that has been the case. Although the party has given way to some fatigue, the punch bowl is still on the table and the biotech upswing continues.
Wednesday, April 17, 2013
Investing in Biotech Stem Cell Research Companies / Companies / BioTech
By: TLSReport
Naysayers may harp on the low market valuations of stem cell companies, but Geoff MacKay has an insider's perspective. The Alliance for Regenerative Medicine chairman and Organogenesis Inc. president and CEO asserts that though the regenerative medicine and cell technology industry is still largely in phase 1/2, phase 3 and commercial success are imminent. In this interview with The Life Sciences Report, MacKay explains the promise of cell therapies for both patient health and investors' portfolios.
The Life Sciences Report: Congratulations on being elected chairman of the board of the Massachusetts Biotechnology Council (MassBio). After almost three decades, it's the nation's oldest biotech trade organization. That really speaks to the respect that your peers have for you. Could you tell me a bit about MassBio? What is it about?
Read full article... Read full article...
Friday, April 12, 2013
Stocks that Can Mend the Biotech Market / Companies / BioTech
By: TLSReport
Markets are not efficient—at least not in the short term. WBB Securities President Stephen Brozak admits to frustration when he sees small-cap companies with valuations that are disengaged from market realities. But Brozak's experience as a biotech investor, banker and analyst has taught him to be patient with these disconnection syndromes, and he now delights in prospects offered by select bargain-basement opportunities. In this interview with The Life Sciences Report, Brozak touches on 10 names that have been flying far below the radars of most investors.
The Life Sciences Report: Steve, you have something you'd like to get off your mind. Tell me.
Tuesday, April 09, 2013
Biotechs Stocks with Staggering Profit Potential / Companies / BioTech
By: TLSReport
When it comes to picking biotech stocks, does a buyside perspective matter more than a sellside? Not according to Zacks Investment Research Analyst Grant Zeng, who has straddled the divide. What really matters is research of uncompromised quality. In this interview with The Life Sciences Report, Zeng offers a primer on what he looks for in a biotech investment, and names companies with the potential for big returns.
The Life Sciences Report: Grant, you've been on both the buyside and the sellside. Today you're an analyst at Zacks, a noninvestment bank firm that does not have to solicit business from the companies on which it performs due diligence and research. Is there an advantage for investors in this research model?
Read full article... Read full article...
Saturday, March 30, 2013
Big Growth Stories in Bio-technology Stocks Sector / Companies / BioTech
By: TLSReport
As a former biotechnology researcher and 25-year Wall Street veteran, Griffin Securities Inc. Analyst and Scientific Director Keith Markey understands how novel, cutting-edge technology can produce extraordinary new products that bring in revenues with double-digit growth potential. Markey reveals his best ideas in this Life Sciences Report interview, providing his growth thesis for every name and describing why each has potential for at least a double.
The Life Sciences Report: You've been an analyst for more than two decades, and before that you were a wet lab bench guy working in the realm of endocrinology and neurobiology. You came to the financial industry when biotechnology was still nascent. How has drug discovery changed over time?
Read full article... Read full article...